Your session is about to expire
← Back to Search
Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia (LOW-TMP Trial)
LOW-TMP Trial Summary
This trial will compare the efficacy and safety of a reduced treatment dose of TMP-SMX for PJP against the standard-of-care.
LOW-TMP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowLOW-TMP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LOW-TMP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had a bad reaction to TMP-SMX or any sulfa drugs before.I have been diagnosed with porphyria.I have recently visited a hospital for my condition.I have received treatment for PJP for more than 72 hours.I cannot give consent and do not have a healthcare proxy, or I refuse to consent, or I cannot be reliably contacted.I have a weakened immune system due to a condition or treatment.You have been diagnosed with a lung infection called PJP using specific medical criteria.I have been diagnosed with G6PD deficiency.My liver enzyme levels are very high.I have been taking medication to prevent a specific lung infection for at least 4 weeks.
- Group 1: Reduced dose TMP-SMX
- Group 2: Standard dose TMP-SMX
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being administered this treatment?
"This trial is no longer recruiting patients. The study was first posted on 6/1/2022 and was most recently updated on 4/5/2022. If you are looking for other studies, there are 968 trials actively admitting patients with pneumocystis and 15 studies for trimethoprim-sulfamethoxazole currently seeking participants."
Are we still looking for participants for this experiment?
"Unfortunately, this particular study is not currently seeking new participants. However, it was last updated on April 5th, 2022 and originally posted June 1st of the same year. There are 983 other trials that are actively recruiting patients right now."
Does this research include patients that are over 55 years old?
"According to the requirements listed, people aged 18 to 100 are eligible for this trial. Out of the 788 trials available for patients over 65 and 242 studies for those under 18, this is the most promising opportunity."
How can I get involved in this experiment?
"This clinical trial is looking for 300 patients who currently have pneumocystis and meet the following criteria: they must be between the ages of 18 and 100, immunocompromised (including but not limited to HIV, solid organ transplant, solid tumors, hematological stem cell transplant and malignancies, systemic diseases, chemotherapy, long term corticosteroid use, and immunosuppressive therapies, as well as primary immunodeficiencies), presentation to a day hospital or emergency department or admitted to hospital. Proven or probable diagnosis of PJP using an adapted version of the 2021 EORTC/MS"
What infections does trimethoprim-sulfamethoxazole commonly target?
"Trimethoprim-sulfamethoxazole is an effective antibiotic treatment for shigella sonnei-caused enteritis, otitis media, and shigellosis."
Is this the first investigation of trimethoprim-sulfamethoxazole?
"There are currently 15 ongoing trimethoprim-sulfamethoxazole trials, 3 of which have progressed to Phase 3. While the majority of these research projects are based in Montreal, Quebec - there are a total of 38 locations running clinical trials for this medication."
Has the FDA cleared trimethoprim-sulfamethoxazole for use?
"There is some evidence from prior trials to support the efficacy of trimethoprim-sulfamethoxazole, as well as multiple rounds of data demonstrating its safety. Consequently, our team has rated it a 3 on our scale."
Share this study with friends
Copy Link
Messenger